Full Text Full Text (PDF) Correction (v158,p834) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Simpson, G. M. Articles by Turner, R. M. Search for Related Content PubMed Citation Articles by Simpson, G. M. Articles by Turner, R. M. Schizophrenia Spectrum Disorders Other Neuroleptics

Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia

OBJECTIVE: This study explored the relative efficacy of three different doses of clozapine. METHOD: Fifty patients who met Kane et al.’s criteria for treatment-refractory schizophrenia or schizoaffective disorder were studied. All subjects were randomly assigned to 100, 300, or 600 mg/day of clozapine for 16 weeks of double-blind treatment. Forty-eight patients completed this first 16 weeks. Of the 50 patients, 36 went on to second and third 16-week trials of double-blind treatment at the remaining doses. RESULTS: Four subjects (8%) responded to the first 16-week condition, and one subject (2%) responded to the next 16-week crossover condition. A chi-square comparison of the response rates from the three dose groups failed to show a significant effect. An analysis of variance (ANOVA) com­parison of Brief Psychiatric Rating Scale—Anchored (BPRS-A) total change scores from  baseline to last observation carried forward showed a significant dose effect (600>300>100 mg/day) at 16 weeks of treatment. A crossover ANOVA of the BPRS-A total scores from the 48-week study also showed that the main effect for dose was highly significant; the 100-mg/day dose gave the higher (poorer) values, and the 300- and 600-mg/day doses gave equal (better) values. Gender played a role in clinical response to treatment at 100 mg/day. CONCLUSIONS: Clozapine treatment at 100 mg/day was less effective than at 300 or 600 mg/day. At 100 mg/day, women responded better than did men. The 600 mg/day group had the best results, but an occasional patient required up to 900 mg/day. Overall response rates were lower than expected.

This article has been cited by other articles:

				J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature Schizophr Bull, February 26, 2008; (2008) sbn009v1. [Abstract] [Full Text] [PDF]

				S. M. Silverstein Integrating Jungian and Self-Psychological Perspectives Within Cognitive-Behavior Therapy for a Young Man With a Fixed Religious Delusion Clinical Case Studies, June 1, 2007; 6(3): 263 - 276. [Abstract] [PDF]

				S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics Am J Psychiatry, February 1, 2006; 163(2): 185 - 194. [Abstract] [Full Text] [PDF]

				J. de Leon, S. C. Armstrong, and K. L. Cozza The Dosing of Atypical Antipsychotics Psychosomatics, June 1, 2005; 46(3): 262 - 273. [Abstract] [Full Text] [PDF]

				J. M. Davis, N. Chen, and I. D. Glick A Meta-analysis of the Efficacy of Second-Generation Antipsychotics Arch Gen Psychiatry, June 1, 2003; 60(6): 553 - 564. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us